Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Tarsus Pharmaceuticals announced robust second quarter 2026 financial results driven by 69% year-over-year growth in net product sales of their FDA-approved eye drop XDEMVY for Demodex blepharitis. The company increased its full-year sales guidance and advanced its pipeline with the pending acquisition of Alkeus Pharmaceuticals, adding a Phase 3 cl…